Case Reports in Oncology最新文献

{"title":"Urinary Stricture due to Localized Urethral AL Amyloidosis: A Case Report and Literature Review.","authors":"Marialaina Carter, Samuel Hall, Rosetta Campbell, Omar Alkharabsheh, Nabin R Karki","doi":"10.1159/000547759","DOIUrl":"https://doi.org/10.1159/000547759","url":null,"abstract":"<p><strong>Introduction: </strong>The deposition of amyloid fibrils in various organs is a hallmark of amyloidosis, which is rarely isolated to a single site. We present a case of localized AL amyloidosis in a 23-year-old male who presented with hematuria from urethral stricture. Biopsy during urethroplasty confirmed amyloid deposition, and liquid chromatography-mass spectrometry identified the AL subtype.</p><p><strong>Case presentation: </strong>A comprehensive workup, including bone marrow biopsy, fat pad biopsy, cardiac workup, and serum protein electrophoresis, excluded monoclonal disorder as well as widespread amyloid involvement. The patient underwent a two-stage urethroplasty and no evidence of recurrence locally or systemically during follow-up.</p><p><strong>Conclusion: </strong>This case emphasizes the importance of considering urethral amyloidosis in the differential diagnosis of urethral strictures, amyloid typing, and workup to excluding systemic involvement. True localized AL amyloidosis does not need amyloid-directed therapy initially but warrants close monitoring.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1239-1246"},"PeriodicalIF":0.7,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemiparesis during Initial Systemic Therapy for Breast Cancer.","authors":"Miyuki Kitahara","doi":"10.1159/000547733","DOIUrl":"https://doi.org/10.1159/000547733","url":null,"abstract":"<p><strong>Introduction: </strong>Docetaxel (DTX) is a standard chemotherapy agent used to treat breast cancer, with peripheral neuropathy being one of its major adverse effects.</p><p><strong>Case presentation: </strong>We report a case of a cervical spinal cord tumor in a 62-year-old woman that developed during DTX treatment for breast cancer, requiring differentiation from DTX-induced peripheral neuropathy. The patient, diagnosed with cT2N0M0 Stage IIA breast cancer, was scheduled for four cycles of epirubicin/cyclophosphamide therapy followed by four cycles of DTX. After the first cycle of DTX, she developed progressively worsening numbness in both upper and lower limbs and pain in the right lower limb. By the second cycle, hemiparesis in the right upper and lower limbs made walking difficult. Magnetic resonance imaging revealed a cervical spinal cord tumor, which was confirmed as a meningioma upon pathological examination.</p><p><strong>Conclusion: </strong>Following tumor resection, the patient regained the ability to walk normally. Currently, at 8 months post-surgery, only mild numbness persists in both limbs.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1222-1227"},"PeriodicalIF":0.7,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Myeloid Leukemia with <i>BCR::ABL1</i>+ Fusion: A Report of Two Cases and Review of Literature.","authors":"Dominik S Dabrowski, Abhilasha Ghildyal, Alice S Yu, Xiaoming Fan, Rusella Mirza, Long Jin, Min Dai, Rodney E Shackelford, Eric X Wei","doi":"10.1159/000547487","DOIUrl":"https://doi.org/10.1159/000547487","url":null,"abstract":"<p><strong>Introduction: </strong><i>BCR::ABL1+</i> fusion is associated with chronic myelogenous leukemia and precursor B acute lymphoblastic leukemia. Though rare, there has been continued reporting of acute myeloid leukemia (AML) with <i>BCR::ABL1+</i> fusion. We report two such cases.</p><p><strong>Case presentations: </strong>The first is a 38-year-old male, who has been human immunodeficiency virus positive since 2004, with leukocytosis and numerous circulating blasts that showed evidence of a <i>BCR::ABL1+</i> fusion rearrangement in the 91% of the cells analyzed via fluorescence in situ hybridization. He responded well to tyrosine kinase inhibitor combined chemotherapy. He was free of disease at 2 years of treatment but showed minimal residual disease at the molecular level 6 years after initial presentation. The second is a 69-year-old female with anemia, thrombocytopenia, and 25% circulating blasts. Her flow cytometric analysis revealed a CD34+ and CD117+ immature myeloid blast population. Her initial cytogenetic analysis showed t(9;22) translocation with loss of chromosomes 12 and 17, derivative of chromosome 1, pericentric inv(17), and two small marker chromosomes. Reverse transcription polymerase chain reaction revealed p190 and p210 <i>BCR::ABL1+</i> fusion transcripts. She received multiple combinations of chemotherapy, consisting of dasatinib, cytarabine, and idarubicin. The patient showed persistent disease at 18 months of therapy with detectable <i>BCR::ABL1+</i> transcripts in peripheral blood. The complex genetic profile of her cancer is likely the reason for her poor response, compared to the first patient. She was lost to follow-up.</p><p><strong>Conclusion: </strong>With ever improving therapy available and few cases in the literature, correct and timely diagnosis with proper management of AML with <i>BCR::ABL1</i>+ is warranted.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1198-1206"},"PeriodicalIF":0.7,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robot-Assisted Simultaneous Distal Pancreatectomy and Sigmoidectomy for Synchronous Pancreatic and Colon Tumors: A Case Report.","authors":"Daisuke Tomita, Yudai Fukui, Satoshi Okubo, Yutaro Naka, Junichi Shindoh, Shuichiro Matoba, Masaji Hashimoto, Hiroya Kuroyanagi","doi":"10.1159/000547602","DOIUrl":"https://doi.org/10.1159/000547602","url":null,"abstract":"<p><strong>Introduction: </strong>With advancements in cancer diagnostics and treatment, the detection of multiple primary tumors has become more common, prompting the need for effective and minimally invasive surgical strategies. Simultaneous multi-organ resections can reduce surgical stress and promote early postoperative recovery, which is particularly beneficial when timely initiation of adjuvant therapy is essential. Robot-assisted surgery offers enhanced precision and dexterity, making it a valuable option for complex multivisceral resections. In this case, we performed simultaneous robot-assisted pancreatic resection and colectomy in a patient who also required curative chemoradiotherapy for esophageal cancer, allowing for the prompt initiation of postoperative treatment.</p><p><strong>Case presentation: </strong>The patient was a 76-year-old man diagnosed with a neuroendocrine tumor in the pancreatic tail, early-stage esophageal squamous cell carcinoma, and early-stage sigmoid colon adenocarcinoma. Surgical indications were confirmed for all three lesions. A multidisciplinary team decided to perform simultaneous robot-assisted distal pancreatectomy and sigmoidectomy using the da Vinci^® Xi system, followed by curative chemoradiotherapy for the esophageal cancer. We minimized the number of additional ports (total of seven) by sharing some between the two procedures, while maintaining optimal instrument maneuverability. The total operative time was 375 min (console time, 265 min), with no perioperative complications. The patient was discharged on postoperative day 12 and subsequently underwent chemoradiotherapy for esophageal cancer.</p><p><strong>Conclusion: </strong>This case highlights the feasibility and safety of robot-assisted simultaneous distal pancreatectomy and sigmoidectomy. While robotic multivisceral resections offer several advantages, thorough preoperative planning, surgical expertise, and appropriate patient selection remain essential.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1214-1221"},"PeriodicalIF":0.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous Hepatic Perfusion Melphalan Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in a Patient with Metastatic Uveal Melanoma.","authors":"Stephan S Leung, Carin F Gonsalves, Marlana Orloff, Robert D Adamo, Christina C Lindenmeyer, David J Eschelman","doi":"10.1159/000547005","DOIUrl":"https://doi.org/10.1159/000547005","url":null,"abstract":"<p><strong>Introduction: </strong>Percutaneous hepatic perfusion using the HEPZATO KIT^™ (Delcath Systems, Inc., Queensbury, NY) is a US Food and Drug Administration approved treatment for liver metastases from uveal melanoma. We discuss the development of sinusoidal obstruction syndrome/veno-occlusive disease after treatment using percutaneous hepatic perfusion.</p><p><strong>Case presentation: </strong>The patient is a 49-year-old male with a history of hepatic metastatic uveal melanoma. Despite several rounds of trans-arterial chemoembolization, the patient had progression of liver disease and was then treated with percutaneous hepatic perfusion. Several weeks later, the patient was found to have liver injury and was diagnosed with biopsy-proven sinusoidal obstruction syndrome. He was treated with defibrotide and symptoms resolved, but passed away several months later due to progression in metastatic disease.</p><p><strong>Conclusion: </strong>To our knowledge, this represents the first case of sinusoidal obstruction syndrome after melphalan administration for percutaneous hepatic perfusion. Rapid progression of disease versus sinusoidal obstruction disease must be considered in patients who present with signs of liver injury/failure after this procedure as prompt diagnosis and treatment are crucial.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1145-1151"},"PeriodicalIF":0.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peritoneal Carcinomatosis with Gray-to-Black-Colored Peritoneum and Intestines Treated with Nivolumab: A Case Report.","authors":"Yuki Muroyama, Yuya Yoshida, Shiori Ishikawa, Fumiyoshi Fujishima, Takashi Suzuki","doi":"10.1159/000547654","DOIUrl":"https://doi.org/10.1159/000547654","url":null,"abstract":"<p><strong>Introduction: </strong>Peritoneal carcinomatosis of unknown primary is a life-threatening condition that presents diagnostic and therapeutic challenges with poor prognosis. In 2021, nivolumab was approved for carcinoma of unknown primary in Japan.</p><p><strong>Case presentation: </strong>A 70-year-old male underwent first-line nivolumab treatment for peritoneal carcinomatosis of unknown primary, in accordance with the patient's wishes. Four months after initiating treatment, he developed immune-related adverse event (irAE) hepatitis, which responded to methylprednisolone; however, the patient died a few days later. Autopsy revealed an uncommon presentation of thick, firm, gray peritoneum with globally gray-to-black ischemic intestines, massive adhesions, ascites, and disseminated peritoneal nodules. No evidence of superior mesenteric artery occlusion, segmental necrosis, or typical features of ischemic colitis or nonocclusive mesenteric ischemia was evident. Histological findings revealed fibrous thickening of the peritoneum. Pathological examination collectively suggested that the primary site of the peritoneal carcinomatosis was the non-mucinous adenocarcinoma, not otherwise specified, and mucinous adenocarcinoma of the appendix, which had not been detected on imaging or endoscopy. The final staging was pT4b, pN1a, pM1c, pStage IVC based on the TNM Classification (8th edition).</p><p><strong>Conclusion: </strong>Although irAE colitis is well documented, peritoneal complications associated with immune checkpoint blockades have been scarcely reported in the literature, especially gray-colored peritoneum as in this case. The etiology is still unclear, but might collectively involve inflammation, stromal fibrosis, microscopic tumor invasion, and metabolic dysregulation in the tissue/tumor microenvironment. The unusual peritoneal presentation warrants further case accumulation and investigation into its pathogenesis to improve clinical management strategies.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1193-1197"},"PeriodicalIF":0.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nasopharyngeal Carcinoma Presenting with Extensive Osseous Metastases and Intracranial Involvement: A Case Report.","authors":"Mariana Marrero Castillo, Benedict Amalraj, Anil Ananthaneni, Kavitha Beedupalli","doi":"10.1159/000547582","DOIUrl":"https://doi.org/10.1159/000547582","url":null,"abstract":"<p><strong>Introduction: </strong>Nasopharyngeal carcinoma (NPC) rarely presents with extensive osseous metastases and intracranial involvement as initial manifestations, posing diagnostic challenges. This report details an unusual case, highlighting its unique clinical course and the importance of considering NPC in atypical metastatic presentations, particularly when an association with Epstein-Barr virus (EBV) is identified.</p><p><strong>Case presentation: </strong>An approximately 60-year-old female presented with a progressively enlarging forehead lesion, headaches, and subsequent findings of calvarial lytic lesions with intracranial extension. Comprehensive imaging (MRI, computed tomography [CT], PET/CT) revealed extensive fluorodeoxyglucose-avid osseous metastases and identified a hypermetabolic primary mass in the nasopharynx. Histopathology of a calvarial lesion confirmed poorly differentiated squamous cell carcinoma, with EBV in situ hybridization positivity, leading to the diagnosis of metastatic EBV-associated NPC. Treatment involved surgical excision of the symptomatic calvarial lesion, palliative radiation to thoracic spine metastases, and systemic therapy with pembrolizumab and denosumab, chosen by the patient over chemotherapy. Despite initial partial symptomatic relief, the patient's condition deteriorated, and she transitioned to hospice care.</p><p><strong>Conclusion: </strong>This case underscores the diagnostic complexities of NPC with an atypical metastatic pattern. It emphasizes the critical role of comprehensive diagnostic workup, including EBV testing, and multidisciplinary management. While advanced NPC carries a poor prognosis, this report contributes to understanding its diverse presentations and reinforces the need for patient-centered therapeutic decisions.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1207-1213"},"PeriodicalIF":0.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid: Successful Treatment with Dupilumab while Maintaining Immunotherapy.","authors":"Cristina-Maria Florea, Laurent Parmentier, Mohamed Abdou, Grégoire Berthod","doi":"10.1159/000547431","DOIUrl":"https://doi.org/10.1159/000547431","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors (ICIs) represent a new class of antitumor agents in oncology. Their use has been associated with a specific safety profile, known as immune-related adverse events (irAEs), with dermatological toxicities being the most frequently encountered.</p><p><strong>Case report: </strong>We report the case of a bullous pemphigoid (BP) in a metastatic melanoma patient, treated with ipilimumab and nivolumab. This immune-mediated toxicity was controlled by using dupilumab as a steroid-sparing therapy, allowing the reintroduction of immunotherapy without relapse.</p><p><strong>Conclusion: </strong>This case illustrates the complexity of managing some dermatological irAEs and the need for better treatment strategies. Dupilumab is a promising agent for cutaneous irAEs, including ICI-BP. To our knowledge, our case is the first one in which a rechallenge with an ICI was attempted after a dupilumab treatment for an ICI-BP.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1171-1177"},"PeriodicalIF":0.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extramedullary Plasmacytoma of the Base of Tongue: A Case Report.","authors":"Colton Cox, Kyren Maynard, Guy Jones, Santhosh Ambika","doi":"10.1159/000547433","DOIUrl":"https://doi.org/10.1159/000547433","url":null,"abstract":"<p><strong>Introduction: </strong>Extramedullary plasmacytoma (EMP) is a rare plasma cell neoplasm typically arising outside the bone marrow. EMP involving the base of the tongue is particularly uncommon, posing diagnostic and therapeutic challenges due to its rarity and nonspecific presentation.</p><p><strong>Case presentation: </strong>A 65-year-old male presented with progressive dysphagia, odynophagia, and significant weight loss. Biopsy of a tongue base mass initially suggested a high-grade hematolymphoid neoplasm, subsequently confirmed as EMP on secondary pathology review. Positron emission tomography-computed tomography (PET/CT) imaging revealed localized fluorodeoxyglucose-avid involvement of the tongue base and bilateral cervical lymph nodes. Bone marrow biopsy was negative for systemic disease. The patient was treated with definitive radiation therapy, resulting in complete clinical and radiologic resolution of disease on follow-up PET/CT 3 months posttreatment. Surveillance studies showed no progression to multiple myeloma.</p><p><strong>Conclusion: </strong>Clinicians should maintain a high index of suspicion for EMP in patients presenting with persistent oropharyngeal symptoms and atypical masses. Early recognition and definitive radiation therapy can lead to excellent outcomes and prevent progression to systemic disease.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1178-1185"},"PeriodicalIF":0.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reirradiation for Sinonasal Adenoid Cystic Carcinoma in a Low-Middle Income Setting: A Case Report and Literature Review.","authors":"Wael Kaabia, Alia Mousli, Najla Attia, Bouchra Naija, Asma Ghorbel, Khadija Ben Zid, Semia Zarraa, Rim Abidi, Chiraz Nasr","doi":"10.1159/000547432","DOIUrl":"https://doi.org/10.1159/000547432","url":null,"abstract":"<p><strong>Introduction: </strong>Reirradiation for recurrent adenoid cystic carcinoma (ACC) of the head and neck poses significant clinical challenges, particularly in low- and middle-income countries where access to advanced radiation modalities such as proton or carbon ion therapy is limited. Given the tumor's radioresistant nature and the risk of cumulative toxicity to critical structures, reporting experiences with accessible and precise photon-based techniques remains essential. This case highlights the potential of volumetric-modulated arc therapy (VMAT) as a feasible reirradiation option in such settings.</p><p><strong>Case presentation: </strong>We report the case of a 79-year-old male with a history of left ethmoidal sinus ACC initially treated with surgery followed by cobalt-based radiotherapy. Eighteen years later, the patient presented with an inoperable local recurrence. A multidisciplinary tumor board recommended reirradiation using VMAT. A total dose of 60 Gy in 30 fractions was delivered, with careful dosimetric planning to respect cumulative tolerance thresholds of organs at risk (OAR). The treatment was well-tolerated, with no acute grade ≥3 toxicities. Post-treatment imaging showed a marked reduction in tumor volume, and the patient had no severe late toxicity during follow-up or distant metastasis.</p><p><strong>Conclusions: </strong>This case illustrates the potential role of VMAT as a viable reirradiation strategy for head and neck ACC, particularly in resource-limited settings. It emphasizes the importance of individualized treatment planning, accurate dose delivery, and multidisciplinary evaluation in achieving tumor control while minimizing toxicity. Such experiences contribute valuable insights into the management of complex recurrent tumors, where therapeutic options are limited.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1152-1159"},"PeriodicalIF":0.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}